Seres Therapeutics
在场
高管
查看带有其 16 名主要高管的组织结构图
Seres Therapeutics 搜索最多的简介
- Eric Shaff, Director, President and Chief Executive Officer
- Stephen Berenson, Chairman of the Board
- Paul Biondi, Director
高管在Seres Therapeutics变化
- Marella Thorell已作为Chief Financial Officer加入公司 (新闻发布的2024二月26号).
- David Arkowitz, Executive Vice President, Chief Financial Officer and Head of Business Development, 正在办理退休 (新闻发布的2024二月26号).
创建提醒
跟踪 Seres Therapeutics 的高管变动
生物技术
Seres Therapeutics 拥有 2,280 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
Seres Therapeutics 的最新新闻稿
- Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference | Seres Therapeutics
- Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates | Seres Therapeutics
- Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022 | Seres Therapeutics
- Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock | Seres Therapeutics
- Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection | Seres Therapeutics
- Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | Seres Therapeutics
- Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
- Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
- Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates | Seres Therapeutics
- Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022 | Seres Therapeutics
- View more press releases Close
通过电子邮件
